Recruiting

Testing two drugs together to prevent cancer from returning after chemotherapy and radiation

Plain-English translation of NCT06093061 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

RIBBON-LA-01 is testing whether tislelizumab and metronomic capecitabine, given together for 12 months after standard chemotherapy and radiation, can improve survival in patients with advanced nasopharyngeal cancer that still shows signs of disease after initial treatment. The trial focuses on patients whose cancer had certain high-risk features or who still have detectable virus markers after the first round of chemotherapy. The goal is to see if this maintenance treatment can prevent the cancer from coming back or spreading.

Some patients with advanced nasopharyngeal cancer don't respond completely to standard chemotherapy alone, even with radiation therapy. This trial exists to test whether adding a longer course of this medication afterward can help stop cancer from returning in these higher-risk patients.

Do you qualify?

You likely qualify if…

you are at least 21 years old
you have been diagnosed with advanced nasopharyngeal cancer (stage III or IVA)
you have completed 3 cycles of initial chemotherapy with cisplatin and gemcitabine
you still have detectable virus markers in your blood after those 3 cycles of chemotherapy
you are in good overall health with an ECOG performance status of 0 or 1
you are willing and able to use reliable birth control during the study and for 4 months after your last dose of medication (if of childbearing potential)

You likely don't qualify if…

you have previously received immunotherapy drugs (anti-PD-1, anti-PD-L1, anti-PD-L2, or similar immune-boosting medications)
you have an active autoimmune disease like rheumatoid arthritis or lupus, or a history of one that comes back
you have cancer that has spread to your brain or spinal fluid
you are currently taking high doses of steroids or other strong immune-suppressing medications (started within 2 weeks of the trial)
you have had another type of cancer within the past 2 years

What participation looks like

After you complete your initial chemotherapy, you will receive concurrent chemotherapy and radiation (called CCRT), which is standard care. Then, for the next 12 months, you will take the medication as part of this trial while being monitored closely. The main goal is to check whether you remain cancer-free 2 years after starting treatment. You will have regular clinic visits, blood tests, and imaging scans to monitor your progress throughout the year of maintenance treatment and beyond.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Testing two drugs together to prevent cancer from returning after chemotherapy and radiation

What is this trial?

Do you qualify?

What participation looks like

Trial locations